In 2023, Roche said it was removing TNKase for stroke from its phase 3 programmes after a readout of the TIMELESS trial, but ...

Tenecteplase thus officially joins the other stroke thrombolytic approved stateside, alteplase (Activase), which is also ...

The FDA has approved TNKase, a tissue plasminogen, clot-dissolving agent, to treat acute ischemic stroke in adults, according ...

Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.

The US Food and Drug Administration has approved Tenecteplase as first FDA-approved stroke medication in nearly three decades ...

Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...

Tenecteplase is administered as a single, 5-second intravenous bolus, providing a faster and simpler option compared to the ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug ...

alteplase (Activase), which is also marketed by Genentech. Notably, off-label tenecteplase had already become the preferred thrombolytic for acute ischemic stroke before the expanded indication.